latest news releases from the newsroom
Emtec Inc. Announces Increased Credit Facility At Reduced Cost
TRENTON, N.J., Dec. 14, 2004 (PRIMEZONE) -- Emtec Inc. (OTCBB:ETEC), a systems integrator providing technology solutions to enable customers to effectively use and manage data to grow their businesses, today announced that it has entered into an amendment on December 10, 2004, to Loan and Security Agreement with Bank of America Business Capital Corporation (successor by merger to Fleet Capital Corporation) ("BOA"), extending its credit facility through November 21, 2006. This amendment increases Emtec's credit facility from $10 million to $12 million. Emtec can borrow up to a lesser of $12 million minus the outstanding letter of credit obligations or 85 percent of eligible accounts receivable minus the outstanding letter of credit obligations. This amendment reduced Emtec's interest rate from 1.00 percent above the prime rate to 0.25 percent above the prime rate. All other material terms of this agreement remain unchanged.
Nicodrops Receives Order from The Largest U.S. Drug Chain
LA MESA, Calif., Dec. 14, 2004 (PRIMEZONE) -- Nicodrops, Inc. (Pink Sheets:NCDP), developer of the world's first drug-free, non-nicotine smoking cessation lozenge, today announced an agreement with CVS Pharmacies (NYSE:CVS) which will place their product in over 4,000 CVS stores coast to coast. Nicodrops has commenced shipping product to CVS Pharmacy warehouse distribution centers throughout the U.S.
Gardant Pharmaceuticals, Inc.
Bioaccelerate to Co-Develop Anti-Cancer Portfolio of Five Clinical and Three Pre-Clinical Products with Faustus Forschung Cie., Translational Cancer Research GmbH and Faustus Forschung Translational Drug Development AG, Vienna, Austria
NEW YORK, Dec. 14, 2004 (PRIMEZONE) -- Bioaccelerate Holdings Inc. New York (OTCBB:BACL) and Faustus Forschungs Cie. Translational Cancer Research GmbH and Faustus Forschung Translational Drug Development AG, Vienna, Austria, have entered into an agreement regarding the co-development of eight new anti-cancer drug candidates, five of which are in the Clinical development Stage and three in the pre-clinical development stage.
StockGuru.com Initiates Profile Coverage on eMax Holding Corporation
DALLAS, Dec. 14, 2004 (PRIMEZONE) -- StockGuru.com has initiated Profile Coverage on eMax Holding Corporation (Pink Sheets:EMXC). eMax Holding Corporation owns a diverse collection of family entertainment content, and operates through two subsidiaries and two divisions, eMax Music, eMax Net, eMax Studios and Gateways Entertainment, Inc.
Biovitrum AB and Discovery Partners International, Inc. Form Research Alliance
STOCKHOLM, Sweden and SAN DIEGO, Dec. 14, 2004 (PRIMEZONE) -- Biovitrum AB and Discovery Partners International, Inc. (Nasdaq:DPII) today announced that they have entered into a drug discovery and development alliance. Biovitrum and Discovery Partners will work together to identify small molecule lead compounds suitable for advancing targets within the metabolic disease area.